Cinclus’ acid inhibition

Cinclus Pharma AG is developing a fast-acting potassium-competitive acid blocker designed to last longer than proton pump inhibitors and marketed P-CABs to treat severe erosive gastrointestinal reflux disease.

PPIs such as Nexium esomeprazole and Prilosec omeprazole from AstraZeneca plc are standard of care for gastrointestinal reflux disease (GERD) and other acid related diseases. ...